Search clinical trials for: Alpha1-Proteinase Inhibitor (Human)

Total 8572 results

Grifols Therapeutics LLC

Terminated

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

COVID-19

United States, Brazil, Chile, Colombia, Mexico
Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency (SPARK)

Emphysema | Alpha 1-antitrypsin Deficiency (AATD)

United States
Shire

Withdrawn

ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study

Chronic Obstructive Pulmonary Disease | Alpha1-antitrypsin Deficiency
Baxalta now part of Shire
Baxter Healthcare, Ltd. (New Zealand), Baxter Healthcare Pty. Ltd. (Australia)

Completed

Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

Alpha 1-Antitrypsin Deficiency

Australia, New Zealand
Takeda

Withdrawn

A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema

Chronic Obstructive Pulmonary Disease (COPD) | Alpha1-Antitrypsin Deficiency
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Chronic Obstructive Pulmonary Disease | Alpha1-antitrypsin Deficiency

United States, Canada, Australia
Grifols Therapeutics LLC

Terminated

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Grifols Therapeutics LLC

Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

United States
Baxalta now part of Shire

Completed

GLASSIA Infusion Rate Study

Healthy Volunteers | Alpha1-antitrypsin Deficiency

United States
Michael Campos, MD
CSL Behring

Completed

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

Alpha 1 Antitrypsin Deficiency

United States
CSL Behring

Completed

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Emphysema | Alpha 1-proteinase Inhibitor Deficiency

Australia, Canada, Czech Republic, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

Graft-Versus-Host Disease (GVHD) Acute on Chronic

United States
National Institute of Allergy and Infectious Diseases...
Juvenile Diabetes Research Foundation; Immune Tolerance Network (ITN)

Withdrawn

A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II (RETAIN)

Diabetes Mellitus, Type 1

United States
Grifols Therapeutics LLC

Completed

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States
CSL Behring

Completed

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

Emphysema | Alpha1-proteinase Inhibitor Deficiency

Australia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
Grifols Therapeutics LLC

Completed

Deposition of Inhaled Prolastin in Cystic Fibrosis Patients (CF2)

Cystic Fibrosis
Kamada, Ltd.

Completed

Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

New Onset Type-1 Diabetes

Israel
Baxalta now part of Shire

Completed

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

Alpha1-antitrypsin Deficiency

United States, Canada
Baxalta now part of Shire

Terminated

Aralast alpha1-proteinase Inhibitor Surveillance Study

Alpha1-antitrypsin Deficiency

United States
Grifols Therapeutics LLC

Completed

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency (STAMP)

Alpha 1-Antitrypsin Deficiency

United States, United Kingdom
Grifols Therapeutics LLC

Completed

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults (ChAMP)

Alpha 1-Antitrypsin Deficiency

United States
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

Alpha 1-Antitrypsin Deficiency

New Zealand, Australia
Instituto Grifols, S.A.

Completed

Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19

COVID-19

Spain
Blessing Corporate Services, Inc
Takeda Pharmaceuticals North America, Inc.

Withdrawn

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

Pneumonia, Viral | Covid19

United States
University of Dundee

Recruiting

Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function (BATMAN)

Bronchiectasis Adult

United Kingdom
Kamada, Ltd.

Completed

Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

Cystic Fibrosis

Israel
Institute for Human Genetics and Biochemistry
CSL Behring

Completed

Therapy to Elevate CD4 Counts in HIV-1 Disease

HIV Disease

United States
Grifols Therapeutics LLC

Completed

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Alpha 1-Antitrypsin Deficiency

Denmark, Sweden, United Kingdom
Université de Sherbrooke

Terminated

Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis

Cystic Fibrosis

Canada
CSL Behring

Recruiting

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)

Acute-graft-versus-host Disease

United States, Korea, Republic of, Spain, Australia, Germany, Italy, Turkey, Japan
Assiut University

Not yet recruiting

Maternal alpha1 Antitrypsin as a Marker of Intrauterine Growth Restriction in Pre-eclamptic Women

Pre-Eclampsia | Intrauterine Growth Restriction | alpha1 Anti-trypsin
Kamada, Ltd.

Completed

International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema

Emphysema

United Kingdom, Canada, Denmark, Germany, Ireland, Netherlands, Sweden
Children's Hospital Medical Center, Cincinnati
National Institutes of Health (NIH); CSL Behring

Recruiting

Zemaira Eosinophilic Esophagitis Pilot Study (ZEEPS)

Eosinophilic Esophagitis

United States
CSL Behring
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Graft Versus Host Disease (GVHD)

United States
Rabin Medical Center

Unknown

Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients

Lung Transplantation | Bronchiolitis Obliterable Syndrome
Hospital Universitari Vall d'Hebron Research Institute
Bayer; Sociedad Española de Neumología y Cirugía Torácica; Instituto de Salud...

Completed

Inhaled A1AT in Adult Stable Bronchiectasis

Bronchiectasis Adult
Institute for Human Genetics and Biochemistry
Grifols Biologicals, LLC; AIDS Community Research Initiative of America

Terminated

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

HIV Disease

United States
Rabin Medical Center
Kamada, Ltd.

Completed

Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes (AAT Extension)

Type 1 Diabetes | Beta Cell Preservation

Israel
Baxalta now part of Shire
Arriva Pharmaceuticals, Inc.

Completed

Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency

Alpha1-antitrypsin Deficiency

United States
University of Florida

Recruiting

The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study (ACT)

Alpha-1 Antitrypsin Deficiency

United States
Ministry of Health, Saudi Arabia

Unknown

Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Coronavirus

Saudi Arabia
University of Alberta
Shire

Completed

Aralast NP in Islet Transplant

Type 1 Diabetes Mellitus

Canada
Baxalta now part of Shire
Arriva Pharmaceuticals, Inc.

Completed

Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency

Alpha1-antitrypsin Deficiency

United States
Impatients N.V. trading as myTomorrows
Kamada, Ltd.

No longer available

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Alpha 1-Antitrypsin Deficiency | Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Steroid Refractory Acute Graft Versus Host Disease | Alpha-1 Proteinase Inhibitor | Alpha-1 Protease Inhibitor Deficiency | Acute Graft-Versus-Host Reaction Following Bone Marrow...
University of Michigan Rogel Cancer Center
CSL Behring; The Leukemia and Lymphoma Society

Completed

A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease

Graft vs Host Disease

United States
rEVO Biologics

Completed

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)

Preeclampsia

United States
University of Colorado, Denver
Omni Bio Pharmaceutical, Inc.

Completed

The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes

Diabetes | Type 1 Diabetes

United States
Seoul National University Hospital

Active, not recruiting

Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation

Hepatic Veno-Occlusive Disease

Korea, Republic of
Soroka University Medical Center

Unknown

Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery

Post Cardiac Surgery Systemic Inflammatory Response
rEVO Biologics

Completed

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

Antithrombin III Deficiency

United States, France, United Kingdom, Germany, Canada, Austria, Australia, Italy

Search clinical trials for: Alpha1-Proteinase Inhibitor (Human)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations